Does Verona Pharma’s Recent FDA Approval Rally Signal Further Upside in 2025?

If you have been watching Verona Pharma, you are likely wondering whether now is the right time to get in, hold steady, or take some profit off the table. With shares closing recently at $106.43 and a dizzying 120.8% gain since the start of the year, Verona isn’t just keeping up with the market; it’s leaving it behind. Those returns are even more dramatic over the longer term, with the stock up an astonishing 257.4% in the past year and almost fifteen-fold in the last five years.

These enormous gains did not happen in a vacuum. Market optimism around advances in pharmaceutical innovation, strong demand for respiratory treatments, and a broader shift in investor attitudes toward biotech have all played a role in lifting Verona’s share price. While this momentum is impressive, it also prompts a natural question: is all the good news already priced in, or does Verona still have room to run for value-focused investors?

According to our valuation framework, Verona Pharma is currently undervalued in 2 out of 6 key checks, giving it a value score of 2. This is a useful starting point, but headline numbers rarely tell the full story. In the next section, we will walk through each of these valuation approaches to see where Verona really stands. Also, stick around because we’ll discuss a more insightful way to gauge the company’s true value at the end of the article.

Verona Pharma scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

The Discounted Cash Flow (DCF) model estimates a company’s intrinsic value by projecting its expected cash flows over time and then discounting those future flows back to today’s dollars. This approach is widely used because it focuses on the money a business is expected to actually generate for shareholders.

For Verona Pharma, the DCF model uses the two-stage Free Cash Flow to Equity approach. According to the latest data, Verona’s most recent free cash flow is negative $73.6 million, reflecting the significant investment typical at this stage for a biopharma innovator. Analysts expect robust growth, projecting that by 2029 the company’s annual free cash flow could reach $934 million. Looking further out, extrapolated estimates see Verona’s free cash flow exceeding $1.7 billion by 2035. All cash flow figures are presented in US dollars.

Based on these projections, the DCF model calculates Verona Pharma’s intrinsic value at $343.61 per share. This represents a 69.0% discount to the current share price of $106.43. Such a significant gap suggests the market may be underestimating the company’s future cash generation potential.

Story Continues

Result: UNDERVALUED

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Verona Pharma.

VRNA Discounted Cash Flow as at Sep 2025

Our Discounted Cash Flow (DCF) analysis suggests Verona Pharma is undervalued by 69.0%. Track this in your watchlist or portfolio, or discover more undervalued stocks.

The Price-to-Sales (P/S) ratio is a versatile tool for valuing pharmaceutical companies, especially when they are not yet consistently profitable but are experiencing rapid revenue growth. It offers a useful way to compare how the market values each dollar of a company’s sales relative to its peers and the broader industry.

It’s important to note that a company’s expected growth rate and unique risks play a significant role in determining what a “normal” or “fair” P/S ratio should be. Higher growth prospects typically justify a higher multiple, while greater risks or thinner margins will usually bring it down.

Currently, Verona trades on a P/S ratio of 41.38x. This is substantially above the pharmaceuticals industry average of 4.73x, and also higher than the peer average of 17.65x. In situations like this, surface-level comparisons can suggest overvaluation, but they often miss context around company-specific growth rates, margins, and risk profiles.

That is why Simply Wall St introduces the “Fair Ratio,” a custom metric built to reflect Verona’s unique growth forecasts, risk profile, margins, industry positioning and scale. This measure is designed to be a much more tailored benchmark than simply looking at industry or peer averages.

For Verona, the Fair Ratio is 22.75x. Since this is notably below the stock’s current P/S multiple, it indicates the market is assigning a premium relative to what growth, profitability, and risk would suggest is justified.

Result: OVERVALUED

NasdaqGM:VRNA PS Ratio as at Sep 2025

PS ratios tell one story, but what if the real opportunity lies elsewhere? Discover companies where insiders are betting big on explosive growth.

Earlier we mentioned that there is an even better way to understand valuation, so let’s introduce you to Narratives. A Narrative is simply your story behind the numbers. It ties your perspective on Verona Pharma’s business outlook to your own forecasts of revenue, earnings, and margins, then calculates what you believe is a fair value for the stock.

Narratives help bridge the gap between the qualitative story you see unfolding for a company and how that story translates into a real, personalized valuation. With Narratives, you do not need to be an expert; you just select the assumptions that match your view, and the platform turns them into actionable financial insights. All of this is available on Simply Wall St’s Community page, where millions of investors share their perspectives.

By letting you compare your Narrative’s Fair Value with the current market price, Narratives empower you when deciding to buy, sell, or hold. They update dynamically as new information like earnings releases or news arrives, so your perspective can always stay current.

For example, on Verona Pharma, some community Narratives see future growth and EU approvals unlocking major revenue, supporting fair values near $106 per share, while others warn that dependence on one drug and regulatory hurdles could justify much lower fair values.

Do you think there’s more to the story for Verona Pharma? Create your own Narrative to let the Community know!

NasdaqGM:VRNA Community Fair Values as at Sep 2025

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include VRNA.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

No Byline Policy

Editorial Guidelines

Corrections Policy

Source